Earnings ·
Protagonist Therapeutics reported second quarter 2026 financial results, posting net income of $162.8 million ($2.47…
PTGXProtagonist Therapeutics, Inc
Protagonist Therapeutics reported second quarter 2026 financial results, posting net income of $162.8 million ($2.47 basic EPS) compared to a net loss of $34.8 million in the prior year period. The company holds $849.5 million in cash and marketable securities as of June 30, 2026. Revenue surged to $213.5 million, driven by $192.4 million from proportional recognition of Takeda's $200 million rusfertide opt-out payment and $21.1 million for development services. Rusfertide remains under FDA priority review with a PDUFA date in August 2026. ICOTYDE, licensed to Johnson & Johnson, marked its first full quarter of commercial sales following March 2026 approval. The company announced plans to initiate a comprehensive Phase 2b program for PN-881 in early Q1 2027 and has begun Phase 1 studies for the obesity candidate PN-477sc. Protagonist Therapeutics is a biopharmaceutical company focused on discovering and developing peptide therapeutics.